B+
Bull case
20%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
MDXG
MiMedx GroupBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Surgical growth remains strong, Wound volumes show early recovery, cost reductions may support a return to profitability, and the Sanara transaction could expand the surgical opportunity. Management reaffirmed FY2026 standalone sales guidance.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.1.
What can break
Gross margin declined to 69% from 81%, with reimbursement-driven pricing and mix pressure. [#SEC-8K-2026-07-29]
Momentum
43
Value
65
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.80 · Bull $6.50 · Bear $3.20Analysis 2026-08-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $7.40
Why
Momentum43 · Δ7d +6.7
Value65 · Δ7d 0.0
Sentiment63 · Δ7d +2.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +2.1.
Contradictions & invalidation
- • Gross margin declined to 69% from 81%, with reimbursement-driven pricing and mix pressure. [#SEC-8K-2026-07-29]
- • Low coverage, weak direct-peer validation, and unavailable post-release price-reaction and analyst-revision data limit confidence.
- • The core Wound business remains materially impaired, margins have compressed, cash declined to $136 million by June 30, and the proposed acquisition adds financing, integration, and execution risk.
Catalyst clock
2026-07-29
Q2 operating update and FY2026 guidance reaffirmation
Lead driver: Sentiment · See AI snapshot
Momentum
43
9% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
+26.5
Value
65
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-5.9
Sentiment
63
62% active weight
Current posture
7d trendImproving
Δ7d
+2.1
Δ21d
-25.1
Why this grade
Composite grade B. Momentum 42.9 / Value 64.6 / Sentiment 63.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$610.74M
Beta
1.60
Shares Out
145.76M
P/E (TTM)
23.2
P/S (TTM)
2.38
P/FCF (TTM)
14.03
Rev YoY
-34.7%
EPS YoY
-255.9%
Gross Margin
+78.6%
Op Margin
+2.5%
Net Debt
-$143.59M
Current Ratio
5.33
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data